Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Cyclopentolate Hydrochloride
Overview
What is Cyclopentolate Hydrochloride?
Cyclopentolate Hydrochloride Ophthalmic Solution is an anticholinergic prepared as a sterile, borate buffered solution for topical ocular use. It is supplied in two strengths.
Chemical name:
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride
MW=327.85 CHNO ⋅ HCl
The active ingredient is represented by the structural formula:
Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% & 2%
Each mL contains: Active:
Inactives:
Preservative:
What does Cyclopentolate Hydrochloride look like?


What are the available doses of Cyclopentolate Hydrochloride?
Sorry No records found.
What should I talk to my health care provider before I take Cyclopentolate Hydrochloride?
Sorry No records found
How should I use Cyclopentolate Hydrochloride?
Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.
What interacts with Cyclopentolate Hydrochloride?
Sorry No Records found
What are the warnings of Cyclopentolate Hydrochloride?
Sorry No Records found
What are the precautions of Cyclopentolate Hydrochloride?
Sorry No Records found
What are the side effects of Cyclopentolate Hydrochloride?
Sorry No records found
What should I look out for while using Cyclopentolate Hydrochloride?
Cyclopentolate Hydrochloride Ophthalmic Solution should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.
For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes.
Mydriatics may produce a transient elevation of intraocular pressure.
What might happen if I take too much Cyclopentolate Hydrochloride?
Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.
How should I store and handle Cyclopentolate Hydrochloride?
Store in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF).Do not freeze or shake. Protect from light. This product contains no preservative.Store in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF).Do not freeze or shake. Protect from light. This product contains no preservative.Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows: Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% 2 mL NDC 17478-100-02 5 mL NDC 17478-100-1015 mL NDC 17478-100-12 Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2% 2 mL NDC 17478-097-02 5 mL NDC 17478-097-1015 mL NDC 17478-097-12 DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows: Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% 2 mL NDC 17478-100-02 5 mL NDC 17478-100-1015 mL NDC 17478-100-12 Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2% 2 mL NDC 17478-097-02 5 mL NDC 17478-097-1015 mL NDC 17478-097-12 DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows: Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% 2 mL NDC 17478-100-02 5 mL NDC 17478-100-1015 mL NDC 17478-100-12 Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2% 2 mL NDC 17478-097-02 5 mL NDC 17478-097-1015 mL NDC 17478-097-12 DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows: Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% 2 mL NDC 17478-100-02 5 mL NDC 17478-100-1015 mL NDC 17478-100-12 Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2% 2 mL NDC 17478-097-02 5 mL NDC 17478-097-1015 mL NDC 17478-097-12 DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
Non-Clinical Toxicology
Cyclopentolate Hydrochloride Ophthalmic Solution should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes.
Mydriatics may produce a transient elevation of intraocular pressure.
Drug Interactions:
General:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).